Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking ...

IBB is iShares Nasdaq Biotechnology ETF tracking Nasdaq Biotechnology Index. In the last three years, IBB has remained flat and significantly underperformed the S&P 500. For retail investors, we think ...

China is pumping money into its biotech industry, helping launch a new wave of labs and incubators in the country. Experts say this could slow down American innovation in the biotech space. China's ...

The U.S. has been adept at inventing The Next Big Thing, but sometimes stumbles when it comes to exploiting it. From cars to electronics, solar panels, and semiconductors, this pattern has been ...

The world of biotech stocks offers a unique blend of high risk and potentially high reward. Companies operating in this space are constantly pushing the boundaries, making them primed investment ...

Biotechnology is no longer distant science fiction; it’s already a growing force in both national security and local economies. It affects everything from how much you pay at the pharmacy to whether ...

In 2025, fewer biotech deals are getting done, but the dollars behind them are bigger than ever. Having spent years working with emerging and fast-growth life sciences companies, I’ve seen firsthand ...